brigimadlin: Clinical Trials

4 trials of brigimadlin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Completed 2, Active not recruiting 1, Withdrawn 1
Phase 31Completed 1

Follow brigimadlin: new trials by email Literature Review of brigimadlin trials Research Report on brigimadlin

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Brigimadlin - Solid Tumours
Phase 2Active not recruitingBoehringer Ingelheim902024-12-302026-09-29
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures
Ezabenlimab + BI907828 - Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer
Phase 2WithdrawnInstitut BergoniƩ2024-06-142025-09-02
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Brigimadlin - Pancreatic Neoplasms, Solid Tumors
Phase 2CompletedBoehringer Ingelheim992022-12-132026-10-14
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Brigimadlin, Doxorubicin - Liposarcoma, Dedifferentiated
Phase 2 / Phase 3CompletedBoehringer Ingelheim4002022-03-312026-03-02

Conditions studied

Biliary Tract Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Liposarcoma (1)  ·  Lung Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Sarcoma (1)  ·  Tertiary Lymphoid Structures (1)  ·  Triple Negative Breast Neoplasms (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Boehringer Ingelheim (3)  ·  Institut BergoniĆ© (1)

Countries

France (4)  ·  Australia (3)  ·  Belgium (3)  ·  Germany (3)  ·  Japan (3)  ·  Spain (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  Denmark (2)  ·  Italy (2)  ·  Norway (2)

Results publications

PMID 36987836, PMID 38214149

NIH funding

2023 (2)